AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00394966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 619734 Dose 1
Description: SCH 619734 10 mg (4 capsules) x 1 orally approximately 2 hours prior to the administration of the first chemotherapeutic agent on Day 1 of Cycle 1 and on Day 1 of all subsequent cycles (up to five additional cycles)
Study NCT00394966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 619734 Dose 2
Description: SCH 619734 25 mg (4 capsules) x 1 orally approximately 2 hours prior to the administration of the first chemotherapeutic agent on Day 1 of Cycle 1 and on Day 1 of all subsequent cycles (up to five additional cycles)
Study NCT00394966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 619734 Dose 3
Description: SCH 619734 100 mg (2 capsules) x 1 orally approximately 2 hours prior to the administration of the first chemotherapeutic agent on Day 1 of Cycle 1 and on Day 1 of all subsequent cycles (up to five additional cycles)
Study NCT00394966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 619734 Dose 4
Description: SCH 619734 200 mg (4 capsules) x 1 orally approximately 2 hours prior to the administration of the first chemotherapeutic agent on Day 1 of Cycle 1 and on Day 1 of all subsequent cycles (up to five additional cycles)
Study NCT00394966 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo x 1 orally approximately 2 hours prior to the administration of the first chemotherapeutic agent on Day 1 of Cycle 1 and on Day 1 of all subsequent cycles (up to five additional cycles)
Study NCT00028028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Description: Given IV
Study NCT00028028 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00028028 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01631474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-03-01
Description: Topical cream, applied once a day
Study NCT01631474 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Topical cream, applied once or twice a day
Study NCT01631474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-03-01
Description: Topical cream, applied twice a day
Study NCT03527212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SJP-0035 0.001%
Description: Self-administration of 1 drop (approximately 40 µL) of 0.001% SJP-0035 ophthalmic solution into each eye 4 times daily for 4 weeks
Study NCT03527212 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Self-administration of 1 drop (approximately 40 µL) of placebo ophthalmic solution into each eye 4 times daily for 4 weeks
Study NCT01592188 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitively-Based Compassion Training (CBCT)
Description: CBCT is a 12 week program that begins by teaching mindfulness and attention. It then goes on to use new mindfulness skills to consider topics of compassion, or unbiased acceptance and compassion for all other people, both friends, unfamiliar people, and enemies.
Study NCT01592188 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness training
Description: Mindfulness training will consist of 6 weeks training in mindfulness meditation.
Study NCT02488629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCB01A
Description: This study is a single arm, open-label, Phase II trial
Study NCT03840278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasiglucagon
Description: Experimental stable glucagon for use in the iLet Bionic Pancreas
Study NCT03025022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-JNJ-42847922 40 mg
Description: Participants will receive a single 40 mg oral dose of 14C-JNJ-42847922 containing maximally 100 MicroCurie as a 40 milliLitre (mL) solution.
Study NCT01196767 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ropivacaine (in one arm); catheterization (in both).
Description: Parallel study with two groups:~1. ropivacaine (2 mg.mL-1), at the rate of 4 mL.hr-1 through two subcutaneous catheters lateral to the sternum, both alimented by an elastomeric pump.~2. same protocol, with normal saline instead of ropivacaine.
Study NCT01196767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine (in one arm); catheterization (in both).
Description: Parallel study with two groups:~1. ropivacaine (2 mg.mL-1), at the rate of 4 mL.hr-1 through two subcutaneous catheters lateral to the sternum, both alimented by an elastomeric pump.~2. same protocol, with normal saline instead of ropivacaine.
Study NCT03194048 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Chewing Training
Description: FuCT;~* Family training~* Providing optimal sitting posture for children to support oral sensorimotor functions~* Positioning the food to the molar area during every meal to stimulate lateral and rotational tongue movements~* Massage of the upper and lower gums through the front teeth to molar area~* Chewing training to stimulate lateral and rotational tongue movements~* Gradually increasing the food consistency, for 12 weeks in 5 sets (1 set = 20 min) each day
Study NCT03194048 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Classical Oral Motor Exercises
Description: Classical Oral Motor Exercises;~* Family training~* passive and active lip and tongue exercises, for 12 weeks in 5 sets (1 set = 20 min) each day
Study NCT04985253 — intervention group
Intervention type: OTHER
Intervention: prediction of overall survival using Web based PREDICTV2.0 portal
Description: Predict is an online prognostication and treatment benefit tool developed in the UK, using cancer registration and survival data recorded by the Eastern Cancer Registration and Information Centre (ECRIC) for 5694 women diagnosed in East Anglia from 1999-2003.~The model was validated in a second cohort of 5468 women from the West Midlands Cancer Intelligence Unit and is available online (www.predict.nhs.uk) providing 5-and 10-year survival estimates and treatment benefit predictions. Wong et al, tested the predictive accuracy of PREDICT V1.0 in the southeast Asian population. There were 67% Chinese patients while 13% were Indians. They showed concordance in observed and predicted OS in most subgroups except for women whore less than 40 years of age.
Study NCT02443376 — intervention group
Intervention type: DEVICE
Intervention: Complior Analyse System
Description: Pulse Wave Velocity PWV and central Pressure analysis
Study NCT02443376 — intervention group
Intervention type: DEVICE
Intervention: BCM- Body Composition Monitor
Description: BCM - Body Composition Monitor gives information about:~Overhydration Urea distribution volume (V) Total body water, extracellular and intracellular water Lean Tissue Index (LTI) Fat Tissue Index (FTI) Body Cell Mass (BCM)
Study NCT02142452 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral intervention
Description: Behavioral intervention will include a group class for women in their 3rd trimester followed by a mobile texting program to support behavior change postpartum.
Study NCT02142452 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Prenatal Care
Study NCT02940691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir/elbasvir
Description: Grazoprevir/elbasvir (100mg/50mg) once daily for 12 weeks.
Study NCT02866877 — intervention group
Intervention type: OTHER
Intervention: Pharmacokinetic modeling
Description: Timed blood draws and urine collections to model drug clearance
Study NCT01440309 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological: mesenchymal stem cell
Description: Mesenchymal stem cells,5-50 million/kg, Intravenous infusion, One dosage，whether to give another dosage depending on patients' condition
Study NCT02391714 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IUD insertion
Description: The IUD (Mirena® or ParaGard®) insertion procedure will occur in the usual manner for both arms. A bimanual exam will be performed, the speculum placed and the cervix visualized. The cervix will then by cleaned with iodine solution. If you are allergic to iodine, we will use chlorhexidine instead. A tenaculum will be placed on the cervix and a uterine sound will be used to measure cavity length. The Mirena® or ParaGard® IUD will be inserted with the specific introducer.
Study NCT01440309 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ursodeoxycholic acid
Description: 13-15 mg/kg/day, to the end of the study
Study NCT01636895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of suphladoxine/pyrimethamine as IPTp
Description: 3 tablets (single dose)given twice during pregnancy one month apart after quickening
Study NCT01636895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of suphladoxine/pyrimethamine as IPTp
Description: 2 courses of 3 tablets of 500 mg N1-(5,6-dimethoxy-4-pyrimidinyl) sulfanilamide (sulfadoxine) and 25 mg 2,4-diamino-5-(p-chlorophenyl)-6-ethylpyrimidine (pyrimethamine)administered (at least 1 month apart) as DOTs to pregnant mother after quickening
Study NCT01800292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil
Description: Subjects will be started on sildenafil at 20 mg PO TID at the baseline visit. Each individual will serve as his/her own control. Subjects will be evaluated at 3 months, with participation completed at that time.
Study NCT03199703 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Baylis transseptal system group
Study NCT03199703 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard conventional transseptal group
Study NCT02105077 — intervention group
Intervention type: DRUG
Intervention: Anesthesia with inhalative application of xenon gas
Study NCT00700791 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Natural Vitamin E Tocotrienol supplement (TCT)
Description: Oral Vitamin E Tocotrienol Supplement (TCT)
Study NCT00700791 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Natural Vitamin E Tocotrienol Cream (TCT)
Description: Natural Vitamin E Tocotrienol(TCT)Topical Cream
Study NCT00700791 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Placebo
Study NCT00700791 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral Placebo
Study NCT02459756 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Beverage: Placebo (sucrose, glucose, fructose, maltodextrin, malic acid, citric acid, vitamin C, artificial blackcurrant flavouring and low-nitrate water)
Study NCT00700791 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cream
Description: Topical Placebo Cream
Study NCT00700791 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Cream
Description: Topical Placebo Cream
Study NCT00901940 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal (Groups A, C, Y and W-135) Conjugate
Description: 2 x 0.5 mL dose
Study NCT00901940 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal polysaccharide A, C, Y and W135 and Menveo
Description: 1 x 0.5 mL dose of ACWY Vax, 1 x 0.5 mL dose of Menveo
Study NCT04155775 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer electronic health record alert (Best Practice Alert - BPA)
Description: Upon ordering platelets in patients with recent platelet count >50,000, a pop-up within the electronic health system will recommend to not continue with transfuse product order and provide clinical exceptions to continue. Importantly, the alert does not trigger in operating areas, emergency medicine treatment areas, for certain specialties like neurosurgery or for massive transfusion orders.
Study NCT00175903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Daily dose of 1000 to 3000 mg film-coated oral tablets, 250-500 mg twice daily.
Study NCT00175903 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbamazepine Controlled Release (CBZ-CR)
Description: Daily dose of 600-1600 mg CR oral tablets, 200 mg and 400 mg twice daily.
Study NCT00175903 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valproate Extended Release
Description: Daily dose of 1000-2000 mg ER oral tablets, 300 mg and 500 mg twice daily.
Study NCT01948375 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real needle- placebo needle
Description: All acupoints were needled through the pad but just pressed against the skin without penetration by pragmatic placebo needle, while through the pad and into the skin 15 mm by real needle. For each intervention, LI4 and RN12 are needled first in a supine position for 15 minutes; BL36 and BL25 are needled secondly in a prone position for another 15 minutes. After withdrawal of the needle, participants were asked to give answers on perception of skin penetration, needle sensation and acupuncture pain. Acupuncture was given every other day, three sessions for one kind of needle, six sessions in total for each subject. There was a two-day interval between the applications of two kinds of needles.
Study NCT01948375 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: placebo needle - real needle
Description: All acupoints were needled through the pad but just pressed against the skin without penetration by pragmatic placebo needle, while through the pad and into the skin 15 mm by real needle. For each intervention, LI4 and RN12 are needled first in a supine position for 15 minutes; BL36 and BL25 are needled secondly in a prone position for another 15 minutes. After withdrawal of the needle, participants were asked to give answers on perception of skin penetration, needle sensation and acupuncture pain. Acupuncture was given every other day, three sessions for one kind of needle, six sessions in total for each subject. There was a two-day interval between the applications of two kinds of needles.
Study NCT03392636 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Herniotomy
Description: In Mitchell Banks Herniotomy, one of investigators will do herniotomy without opening inguinal canal and in Ferguson Gross Herniotomy , one of investigators will do herniotmy by opening inguinal canal.
Study NCT06390475 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MR Direct Thrombus Imaging (MRDTI)
Description: Both groups will get the same MRDTI, the study is a proof-of-concept study to investigate if MRDTI can reliable distinguish between acute and chronic splanchnic thrombosis.
Study NCT00494494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: topical antibiotic for 10 days plus topical corticosteroids for 1 month
Study NCT00494494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nepafenac
Description: liquid drops, administered three times per day for 1 month in addition to standard care use of topical antibiotic and topical corticosteroid
Study NCT00290511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m\^2 intravenous (IV) over 5-30 minutes on Days 2-4.
Study NCT04226079 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Collection of exhaled breath
Description: Collection of exhaled breath will be analyzed for specific volatile organic compounds which show different distribution between groups
Study NCT01367808 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The subjects will be given placebo twice a day for 5 days prior to the study
Study NCT01367808 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vorikonazole
Description: The subject will be given vorikonazole twice a day for 5 days prior to the study. The dose will be 400 mg twice a day on day one ans 200 mg twice a day on days 2-5.
Study NCT01367808 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: posakonazole
Description: The subjects will be given posaconazole 400 mg twice a day for 5 days prior to the study.
Study NCT03364049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-7162
Description: oral tablets
Study NCT04088812 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo meat derivative + Satiating compound
Description: Subjects will consume 60 g of meat derivative placebo in a brunch type meal with 25 g of the satiating compound diluted in water
Study NCT03364049 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion
Study NCT04088812 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo meat derivative + Satiating compound
Description: Subjects will consume 60 g of meat derivative placebo in a brunch type meal with 25 g of the satiating compound diluted in water
Study NCT02343510 — intervention group
Intervention type: OTHER
Intervention: PCR for chlamydia DNA in primary tubal cancer
Description: PCR for presence of chlamydia DNA in paraffin blocks retrieved for tubal and ovarian tissues in all groups
Study NCT04088812 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental meat derivative + Placebo satiating control
Description: Subjects will consume 60 g of the experimental meat derivative in a brunch type meal with 25 g of satiating compound placebo diluted in water
Study NCT04088812 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Experimental meat derivative + Placebo satiating control
Description: Subjects will consume 60 g of the experimental meat derivative in a brunch type meal with 25 g of satiating compound placebo diluted in water
Study NCT00290511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: 10 mg/m\^2 IV over 5-30 minutes on Day 2.
Study NCT02111616 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Survivorship Care Plan (SCP)
Description: Cancer Survivorship Care Plan (SCP) adapted from JourneyForward template. Each SCP is individualized to patient's care regimen. SCP is delivered at the conclusion of cancer treatment and during the patient's transition visit with nurse practitioner or physician assistant.
Study NCT02111616 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Survivorship Care Plan (SCP)
Description: Cancer Survivorship Care Plan (SCP) adapted from JourneyForward template. Each SCP is individualized to patient's care regimen. SCP is delivered at the conclusion of cancer treatment and during the patient's transition visit with nurse practitioner or physician assistant.
Study NCT02111616 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coordinated PCP visit
Description: Visit with PCP scheduled on behalf of patient at the conclusion of cancer treatment and patient's transition visit.
Study NCT00290511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 IV over 4-6 hours on Day 1 and 8; maintenance Rituximab = 375 mg/m\^2 IV over 4-6 hours on Day 1 only, a single dose every other month for 12 months (6 doses total).
Study NCT00290511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zevalin
Description: 0.3 mCi/kg IV after 4 cycles of R-FND.
Study NCT04483440 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4D-110
Description: 4D-110 drug product developed for gene therapy which comprises an AAV capsid variant (4D-R100) carrying a transgene encoding a codon-optimized human CHM gene.
Study NCT00290511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20 mg by mouth (PO) or IV daily on Days 2-6.
Study NCT00544713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboxymethylcellulose and Glycerin based artificial tear
Description: As directed by Investigator at the end of each study visit: 1 to 2 drops in each eye, 1 to 2 times a day up to every hour while awake
Study NCT00544713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboxymethylcellulose
Description: As directed by Investigator at the end of each study visit: 1 to 2 drops in each eye, 1 to 2 times a day up to every hour while awake
Study NCT02511587 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FSME-Immune vaccination
Description: booster vaccination with FSME-Immune
Study NCT02511587 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FSME-Immune vaccination
Description: booster vaccination with FSME-Immune
Study NCT01927250 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Okada Health and Wellness program
Description: Each participant were encouraged to practice the diet program and art therapy established by the MOA International Corporation, and to receive Okada Purifying Therapy, a domain of biofield therapy, for 3 consecutive months.
Study NCT01655836 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Description: Undergo high dose rate brachytherapy
Study NCT01655836 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo stereotactic body radiation therapy
Study NCT01655836 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality-of-life assessment
Description: Ancillary studies
Study NCT01655836 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire administration
Description: Ancillary studies
Study NCT03592641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Savolitinib
Description: Given PO
Study NCT02465528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceritinib (LDK378)
Description: Ceritinib was to be administered orally once daily at a dose of 750 mg (5 capsules of 150 mg) on a continuous dosing schedule. A complete treatment cycle was defined as 28 days of once daily continuous treatment with ceritinib.